18 citations
,
February 2019 in “Scientific Reports” Trichostatin A helps restore hair-growing ability in skin cells used for hair regeneration.
July 2024 in “Journal of Investigative Dermatology” ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.
13 citations
,
May 2011 in “Bioorganic & Medicinal Chemistry” Changing the 6-position on benzopyran molecules affects insulin release, with some compounds showing strong inhibitory effects.
August 2023 in “Frontiers in Oncology” New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.
14 citations
,
August 2017 in “International Journal of Immunopathology and Pharmacology” Photodynamic therapy improved skin issues from sorafenib when other treatments failed.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
5 citations
,
June 2022 in “Journal of Oncology” Blocking the Hedgehog pathway may help overcome drug resistance in multiple myeloma.
Cyproterone acetate is used for topical treatment of diseases dependent on male hormones.
8 citations
,
July 2024 in “Journal of Advanced Research” CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.
4 citations
,
January 2016 in “Dermatology Review” Cancer treatments often cause skin, nail, and hair problems.
January 2024 in “Wiadomości Lekarskie” Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.
2 citations
,
June 2019 in “Boletín médico del Hospital Infantil de México” Tofacitinib treatment is used for teenagers with alopecia areata.
19 citations
,
October 2016 in “Journal of oncology pharmacy practice” A cancer patient's hair became permanently curly after treatment with nivolumab.
1 citations
,
June 2023 in “Advances in therapy” Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.
September 2023 in “International Journal of Applied Pharmaceutics” The formulated gel is a promising treatment for alopecia areata.
November 2020 in “Journal of The American Academy of Dermatology” Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
16 citations
,
September 1999 in “Journal of Investigative Dermatology Symposium Proceedings”
April 2016 in “Journal of Investigative Dermatology” MEK and BRAF inhibitors increase sebum production and accumulation, which could cause acne-like side effects.
June 2024 in “Journal of medicinal chemistry” A new AI-driven method shows promise for treating hair loss with a peptide-based drug.
March 2026 in “Journal for ImmunoTherapy of Cancer” Long-term data and a team approach are needed to manage chronic side effects from cancer treatments.
September 2024 in “Annals of Medicine and Surgery” Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
30 citations
,
December 2019 in “PLoS ONE” The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.
54 citations
,
February 1994 in “Journal of Investigative Dermatology”
April 2024 in “Journal of pharmacy & pharmacognosy research” A compound from Calophyllum inophyllum L. leaf may help treat non-small cell lung cancer.
January 2026 in “International Journal of Innovative Technologies in Social Science” JAK inhibitors show promise for treating alopecia areata, but more research is needed.
April 2024 in “Journal of translational medicine” MJ04, a new compound, effectively promotes hair growth and is a potential topical treatment for hair loss.
January 2017 in “Seoul National University Open Repository (Seoul National University)” AIMP1 can boost hair growth by increasing stem cell activity.
1 citations
,
June 2021 in “Journal of dermatology and dermatitis” Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.
January 2024 in “Scripta Medica” Nanoparticle delivery can reduce side effects of the cancer drug doxorubicin.
13 citations
,
June 2008 in “International Journal of Dermatology” Sorafenib can cause a unique skin reaction.